

Anti-Cyclin D1 [E3P5S]

Catalog No.	Description
ANA20-5M	6 ml of Ready-to-Use Antibody for use with BioGenex Super Sensitive™ Detection Systems OR equivalent detection system
ANA20-10M	10 ml of Ready-to-Use Antibody in a barcode labeled vial for use with BioGenex Super Sensitive™ Detection Systems and i6000™ Automated Staining Systems
NUA20-UC	1 ml of Concentrated Antibody for use with BioGenex Super Sensitive™ Detection Systems OR equivalent detection system
NUA20-5UC	0.5 ml of Concentrated Antibody for use with BioGenex Super Sensitive™ Detection Systems OR equivalent detection system
AYA20-YCD	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx® Elite/Ultra Staining System, 160 tests
AYA20-50D	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx® Elite/Ultra Staining System, 50 tests

Clone	Species	Ig Class
E3P5S	Rabbit	IgG

Intended Use

For In Vitro Diagnostic Use. This antibody is designed for the specific localization of Cyclin D1 in formalin-fixed, paraffin-embedded (FFPE) tissue sections. Evaluation must be performed by a qualified pathologist.

Summary and Explanation

Cyclin D1 belongs to the Cyclin D family. Cyclin D1 is required for the cell cycle G1/S transition. Cyclin D1 forms a serine/threonine kinase holoenzyme complex with and functions as a regulatory subunit of CDK4 or CDK6. Cyclin D1 also phosphorylates and inactivates the retinoblastoma protein and promotes progression through the G1/S phase. Amplification or overexpression of cyclin D1 plays a pivotal role in the development of various human tumors including parathyroid adenoma, breast tumor, colon tumor, lymphoma, melanoma and prostate tumor. Cyclin D1 also associates with and regulates the activity of transcription factors, coactivators and corepressors that govern histone acetylation and chromatin remodeling proteins.

Storage and Handling

Store at 2-8°C. Fresh dilutions, if required, should be prepared prior to use and are stable and steady for up to one day at room temperature (20-26°C). Diluted antibody preparations can be refrigerated or frozen for extended shelf life.

Principles of the Procedure

Antigen detection by immunohistochemistry (**IHC**) is a two-step process wherein the primary antibody binds to the antigen of interest and that binding is detected by a chromogen. The **primary antibody** may be used in IHC using manual techniques or BioGenex Automated Staining System. Positive and negative controls should always be run simultaneously with all patient specimens.

Reagents Provided

Rabbit Monoclonal Antibody Cyclin D1 is affinity purified and diluted in PBS, pH 7.2, containing 1% BSA and 0.09% sodium azide.

Dilution of Primary Antibody

BioGenex Ready-to-Use antibodies have been optimized for use with the recommended BioGenex Detection System and should not require further dilution.

BioGenex concentrated antibodies must be diluted in accordance with the recommended protocol when used with the recommended BioGenex Detection System.

Recommended Protocol

Refer to the following table for conditions specifically recommended for this antibody. Refer to the BioGenex website for guidance on specific staining protocols or other requirements.

Parameter	BioGenex Recommendations
Control Tissue	Breast Carcinoma as available with Biogenex FB-A20N* & FG-A20N*
Recommended Dilution for Concentrated Antibody	1:20-50 in HK941
Recommended Pretreatment (Manual/i6000)**	EZ-AR2 (HK522-XAK)
Recommended Pretreatment (Xmatrx)	EZ-AR2 Elegance (HX032-YCD)
Antibody Incubation (Manual/i6000)	30-60 min at RT
Antibody Incubation (Xmatrx)	30-60 min hr at 25°C
Detection System for Manual, Xmatrx & i6000 systems***	Use BioGenex Two-Step OR One-Step Super Sensitive™ Polymer-HRP IHC Detection System/DAB; see p. 2 for more information

*FB: positive control barrier slides, FG: positive control non-barrier slides. Xmatrx requires barrier slides.

**Pretreatment times will vary based on individual microwave power.

***For automation systems (Xmatrx-Elite, Xmatrx-Ultra & i6000 Diagnostics), refer to the factory protocols provided with the instrument.

Category	Antibodies	Revision No.	D
Document No.	932-A20N-EN	Release Date	June 01, 2021

Detection System	Two-Step HRP Kit	One-Step HRP Kit	Link and Label Kit
Manual	QD440-XAKE (1000 Test)	QD630-XAKE (1000 Test)	QP300-XAKE (1000 Test)
	QD430-XAKE (1000 Test)		
	QD420-YIKE (500 Test)	QD620-XAKE (500 Test)	QP900-9LE (500 Test)
	QD400-60KE (60 Test)		
Xmatrix - Automation	QD550-YCDE (200 Test)	QD610-YADE (200 Test)	N/A
i6000 - Automation	QD410-YAXE (200 Test)	QD610-YAXE (200 Test)	N/A
For more information, visit www.biogenex.com .			

Precautions

This product contains sodium azide at concentrations of less than 0.1%. Sodium azide is not classified as a hazardous chemical at the product concentrations, but proper handling protocols should be observed. For more information, a Safety Data Sheet (SDS) for sodium azide is available upon request. Dispose of unused reagents according to Local, State and Federal Regulations. Wear suitable Personal Protective Equipment, do not pipette reagents by mouth, and avoid contact of reagents and specimens with skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with copious amounts of water.

Quality Control

Refer to BioGenex detection system documents for guidance on general quality control procedures.

Troubleshooting

Refer to the troubleshooting section in the documentation for BioGenex Detection Systems (or equivalent detection systems) for remedial actions on detection system related issues, or contact BioGenex Technical Support Department at 1-800-421-4149 or support@biogenex.com or your local distributor to report unusual staining.

Expected Results







This antibody stains nucleus in positive cells in formalin-fixed, paraffin embedded tissue sections. An example image of a tissue section stained with this antibody can be found on the product page on the BioGenex website. Interpretation of the staining result is solely the responsibility of the user. Experimental results should be confirmed by a medically-established diagnostic product or procedure.

Limitations of the Procedure

Improper tissue handling and processing prior to immunostaining can lead to inconsistent results. Variations in embedding and fixation or the nature of the tissue may lead to variations in results. Endogenous peroxidase activity or pseudo peroxidase activity in erythrocytes and tissue biotin may result in non-specific staining based on the detection system employed. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive with horseradish peroxidase systems. Improper counterstaining and mounting may compromise the interpretation of results.

Bibliography

1. P. Neumiester, F. Pixley, et.al. Cyclin D1 governs Adhesion and Motility of Macrophages. *Molecular Biology of the Cell*. May 2003; 14(5), 2005-15.
2. V. Baldin, J. Lukas, et.al. Cyclin D1 Is a Nuclear Protein Required for Cell Cycle Progression in G1. *Genes and Development*. May 1993; 7 (5), 812-21.
3. J. Diehl. Cycling to Cancer with Cyclin D1. *Cancer Biology and Therapy*. May-Jun 2002; 1 (3), 226-31
4. M. Shintani, A. Okazaki, et.al. Overexpression of Cyclin D1 Contributes to Malignant Properties of Esophageal Tumor Cells by Increasing VEGF Production and Decreasing Fas Expression. *Anticancer Research*. Mar-Apr 2002; 22 (2A), 639-47.
5. A. Arnold, A. Papanikolaou. Cyclin D1 in Breast Cancer Pathogenesis. *Journal of Clinical Oncology*. 2005 Jun 20; 23 (18), 4215-24.
6. Kiernan JA. *Histological and Histochemical Methods: Theory and Practice*. New York: Pergamon Press 1981.
7. Nadji M, Morales AR. Immunoperoxidase, part 1: the techniques and its pitfall. *Lab Med* 1983; 14:767-770.
8. Omata M, Liew CT, Ashcavai M, Peters RI. Nonimmunologic binding of horseradish peroxidase to hepatitis B surface antigen. A possible source of error in immunohistochemistry. *Am J Clin Pathol*. May, 1980;73(5):626-632.
9. U.S. Congress. *Clinical Laboratory Improvement Amendments of 1988: Final Rule*, 57 FR 7163, February 28, 1992.
10. National Institute for Occupational Safety and Health, (NIOSH), Rockville, MD. Explosive azide hazard, Publication No. 78-127, 1976.

	Temperature Limitation	IVD	In Vitro Diagnostic Medical Device
	Use By Date	LOT	Batch Code
	Non-Sterile		Consult Instructions for Use
	Representative in the European Community		Manufacturer

© 2020, BioGenex Laboratories. All rights reserved.

Category	Antibodies	Revision No.	D
Document No.	932-A20N-EN	Release Date	June 01, 2021